Desentum

Venture Round
desentum.fi Biotech & Healthcare Espoo, Finland
Total Funding $31.3M
Latest Round $31.3M Venture Round
Last Announced Oct 12, 2026
Investors 6 Backers
Decision Makers 5 Verified

About Desentum

Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Venture Round
Global Headquarters Espoo, Finland
Tracked Since Oct 15, 2026

Web & Domain Identity

Official Website desentum.fi
Domain Registered Date Jan 23, 2013

Social & Network Presence

X / Twitter Profile @desentumAIT (56 followers) Created on Jan 2017
LinkedIn Corporate Company Profile

Company Milestones & Timeline

3 Events
  1. Capital Raise

    Raised $31,310,000 · Round

    Backed by Springvest

  2. Milestone

    X account created (@desentumAIT)

    56 followers

  3. Milestone

    Website domain registered

    desentum.fi

Investors & Backers

6
Cascara Ventures
European Innovation Council Fund
Luxembourgian ACME Investments
Springvest
Sto-Rahoitus
VTT Ventures

Funding History

1 Round
Round equity · Oct 12, 2026

Round backers: Springvest

Founders & Leadership

1

Pekka Mattila

Founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts